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Extended-spectrum beta-lactamases (ESBL) of the TEM, SHV, or CTX-M type confer resistance to beta-
lactam antibiotics in Gram-negative bacteria. The activity of these enzymes against beta-lactam antibiotics and
their resistance against inhibitors can be influenced by genetic variation at the single-nucleotide level. Here,
we describe the development and validation of an oligonucleotide microarray for the rapid identification of
ESBLs in Gram-negative bacteria by simultaneously genotyping blaTEM, blaSHV, and blaCTX-M. The array
consists of 618 probes that cover mutations responsible for 156 amino acid substitutions. As this comprises
unprecedented genotyping coverage, the ESBL array has a high potential for epidemiological studies and
infection control. With an assay time of 5 h, the ESBL microarray also could be an attractive option for the
development of rapid antimicrobial resistance tests in the future. The validity of the DNA microarray was
demonstrated with 60 blinded clinical isolates, which were collected during clinical routines. Fifty-eight of them
were characterized phenotypically as ESBL producers. The chip was characterized with regard to its resolution,
phenotype-genotype correlation, and ability to resolve mixed genotypes. ESBL phenotypes could be correctly
ascribed to ESBL variants of blaCTX-M (76%), blaSHV (22%), or both (2%), whereas no ESBL variant of blaTEM
was found. The most prevalent ESBLs identified were CTX-M-15 (57%) and SHV-12 (18%).
The resistance of widespread Gram-negative pathogens such
as Escherichia coli, Klebsiella species, and other Enterobacteri-
aceae against broad-spectrum beta-lactam antibiotics is a se-
vere and growing issue in health care (29, 41, 42). In the
beginning, the resistance to these antimicrobials, including
oxyimino-cephalosporins (e.g., cefotaxime, cefpodoxime, and
ceftazidime), was caused mainly by TEM- and SHV-type ex-
tended-spectrum beta-lactamases (ESBLs), which evolved via
mutation from the classic TEM-1, TEM-2, and SHV-1 en-
zymes (18). Plasmid-mediated derivatives with an extended
substrate spectrum have been known since the early 1980s (24,
44), and other mutational events that affect substrate affinity
for beta-lactamase inhibitors, such as clavulanic acid, lead to
an inhibitor-resistant (IRT) or complex mutant type (CMT)
enzymes (8). During the last 10 years, other ESBL types have
gained increased importance, especially the CTX-M enzymes
(7, 27, 35, 40). The blaCTX-M genes probably emerged through
several mobilization events of their natural homologues in the
genus Klyvera (5, 21, 33, 34, 37, 39) and have undergone evo-
lution since that time. They have intrinsic ESBL activity and
are clustered in five subgroups, designated CTX-M1, CTX-M2,
CTX-M8, CTX-M9, and CTX-M25 (5).
A fast and accurate identification of the antimicrobial resis-
tance of the etiologic pathogen is decisive for the initiation of
an appropriate antimicrobial therapy (36, 43). Routine culture-
based phenotypic ESBL detection usually requires 2 days or
more (48), and the reported sensitivities and specificities of
different tests (50) leave room for improvement. In addition, as
the required confirmatory tests are based on the synergy effect
between antibiotics and inhibitors, the coexistence of the
ESBL with other beta-lactamases can lead to misinterpreted
results (14, 23). Phenotype-based resistance tests also do not
provide gene variant information, which limits their usefulness
for epidemiologic surveillance and refined antimicrobial ther-
apy. Molecular ESBL detection has the potential to improve
ESBL diagnosis, infection control, and epidemiological surveil-
lance. In addition to standard PCR and gene sequencing, sev-
eral molecular ESBL identification techniques have been de-
veloped during the past few years, such as PCR-restriction
fragment length polymorphism (2), PCR-single strand confor-
mation polymorphism (31), real-time PCR (4, 38), or pyrose-
quencing (22, 32) analysis. However, all of these techniques
have an inherently limited multiplexing capacity. The genotyp-
ing of TEM, SHV, or CTX-M beta-lactamases, with more than
300 known variants altogether (http://www.lahey.org/studies/),
technically would be excessive, very costly, and too time de-
manding to be used as a diagnostic aid. DNA microarrays, on
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the other hand, are an increasingly used tool for multiplexed
genotyping. Microarrays targeting resistance determinants
have been described with focus on certain species (30, 45, 46,
49), specific resistance mechanisms (10, 53), or resistance in
Enterobacteriaceae (3, 11, 17). Some examples covered beta-
lactam resistance at the gene family level (25) or investigated
six point mutations within blaSHV (54), the latter technically
pointing toward the refined genotyping of beta-lactamase
genes. To cover all known mutations in a beta-lactamase gene,
we previously described a DNA microarray for the genotyping
of TEM beta-lactamases (19).
In the present study, we describe an advanced DNA mi-
croarray that integrates an updated version of the TEM mi-
croarray (19) with two new modules for the genotyping of
blaSHV and blaCTX-M genes. Because of its unparalleled high
coverage of known variants and information depth, combined
with its short time to result, this assay can be an enabling tool
for epidemiological studies of ESBL outbreaks and infection
control, and it offers an attractive way toward the development
of the rapid molecular testing of ESBLs in the clinical routine.
MATERIALS AND METHODS
Bacterial strains and antibiotic susceptibility determination. As reference
material for the system setup, we used a panel of reference strains and well-
characterized clinical samples (the bla gene of interest was sequenced). Refer-
ence strains included E. coli DH5 (Clontech, Heidelberg, Germany) trans-
formed with plasmid pUC19 (blaTEM-116; New England Biolabs, Frankfurt,
Germany) or pCCR9 (different strains with several blaSHV genes, including
blaSHV-1, blaSHV-2, blaSHV-5, and blaSHV-12; provided by H. Ha¨chler, Institute of
Medical Microbiology, University of Zu¨rich), European Antibiotic Resistance
Surveillance System reference strain UA 1528 (blaTEM-8), and additional E. coli
reference strains provided by W. Witte, Robert Koch Institute, Wernigerode
Branch, Wernigerode, Germany (blaTEM-3 and blaTEM-7). Clinical samples ad-
ditionally harbored blaTEM-1 (several species), blaCTX-M-3 (K. pneumoniae),
blaCTX-M-5 (Salmonella enterica serovar Typhimurium), blaCTX-M-9 (Enterobacter
sp.), blaCTX-M-14 (E. coli), and blaCTX-M-15 (E. coli) and were provided by our
partners in Moscow and Frankfurt am Main.
For the evaluation of the ESBL array, isolates were collected from the De-
partment of Laboratory Medicine at the Robert Bosch Hospital, Stuttgart, Ger-
many (n 22), and the Institute of Medical Microbiology and Infection Control,
J. W. Goethe Universita¨t, Frankfurt am Main, Germany (n  38). They were
recovered from respiratory samples (n  8), swabs (n  27), urine (n  18), and
other sites (n  7). Species identification was carried out with the API 20NE
system (bioMe´rieux, Marcy l’Etoile, France) or the Gram-negative identification
card GN on a Vitek 2XL system. All bacterial strains were routinely cultured at
37°C on Columbia blood agar (Heipha Diagnostika) or grown in Schaedler-
Bouillon (bioMe´rieux, Marcy l’Etoile, France). Plasmid DNA from bacteria was
extracted with the QIAprep Spin Miniprep kit (Qiagen, Hilden, Germany) ac-
cording to the protocol provided by the manufacturer. Antibiotic susceptibility
was determined by disc diffusion (Kirby-Bauer method) on Mueller-Hinton agar
plates according to Clinical and Laboratory Standards Institute standards (13)
and by the Etest method (AB Biodisk, Solna, Sweden) according to the manu-
facturer’s instructions. MICs were determined using the Gram-negative suscep-
tibility card AST-N062 on a Vitek 2XL system (bioMe´rieux, Marcy l’Etoile,
France). Susceptibility was determined for amikacin (AMK), amoxicillin (amoxi-
cilline)-clavulanic acid (AMC), ampicillin (AMX), ampicillin-sulbactam (SAM),
aztreonam, cefaclor (CEC), cefazolin (CFZ), cefepime (FEP), cefoxitin (FOX),
cefotaxime (CTX), cefpodoxime (CPD), ceftazidime (CAZ), ceftriaxone (CRO),
cefuroxime (CXM), ciprofloxacin (CIP), colistin, doxycycline (DOX), fosfomycin
(FOF), gentamicin (GEN), imipenem (IMP), levofloxacin (LEV), meropenem
(MER), mezlocillin (MEZ), moxifloxacin (MXF), nitrofurantion (NIT), pip-
eracillin (PIP), piperacillin-sulbactam (PIP-SUL), piperacillin-tazobactamaz-
treonam (TZP), tetracycline (TET), tobramycin (TOB), and trimethoprim-sul-
famethoxazole (SXT).
Probe design. Multiple sequence alignments of blaTEM, blaSHV, and blaCTX-M
nucleotide sequences were performed to identify sequence variations, mainly
single-nucleotide polymorphisms (SNPs), leading to amino acid exchanges (http:
//www.lahey.org/studies/). Sequence alignments were carried out using ClustalX
(version 1.83) (47), the BioEdit sequence alignment editor (version 7.0.5.3) (20),
or SeqMan II software (version 5.00; DNAStar). This study includes the inte-
gration of previously designed probes, redesigned probes, and de novo-designed
probes for additional SNPs to update the ESBL microarray. For the current
version of the microarray, 150 probe sets for the characterization of polymor-
phisms leading to 59 amino acid substitutions known for TEM, 53 known for
SHV, and 44 known for the different CTX-M beta-lactamases were developed.
Furthermore, four probe sets for CTX-M group identification were included.
The subgroups for CTX-M-8-like and CTX-M25-like genes were examined to-
gether and labeled group M8/M25. The standard probe design was carried out as
described previously (19), with minor modifications. In brief, oligonucleotide
probes of various lengths (14 to 27 bases) were designed to detect single-
nucleotide substitutions within the blaTEM, blaSHV, and blaCTX-M genes, leading
to amino acid exchanges. For each SNP, a probe set of four probes was designed
with identical sequences except the investigated mutation site, which was either
A, G, C, or T. Ideally, the probes were designed with the mutation at the central
position within the probe sequence to maximize perfect match (PM)-to-mis-
match (MM) discrimination. The probe length, melting temperature (Tm), and
free energies of possible secondary structures (e.g., hairpins [Ghairpin] and
dimers [Gdimer]) were calculated with the online tool OligoAnalyzer (http://eu
.idtdna.com/analyzer/Applications/OligoAnalyzer/) by using the default settings
for monovalent ions and DNA concentration (50 mM and 0.25 M). The fol-
lowing values and thresholds were regarded as optimal: Tm  53  3.5°C;
Ghairpin 0 kcal/mol; and Gdimer6 kcal/mol. All probes were designed as
sense probes. The probe sets are named after the position of the amino acid
substitution within the blaTEM, blaSHV, or blaCTX-M sequence. Unless otherwise
noted, amino acid residue numbering followed the standard numbering scheme
for the class A beta-lactamases described by Ambler et al. (1). For 10 amino acid
substitution positions there are two polymorphisms within one triplet leading to
different amino acids. For these, two probe sets (four probes each) were designed
(e.g., TEM 164.1 and 164.2). Six amino acid substitutions occur at the same
position but in different CTX-M beta-lactamase groups. For these, two probe
sets, each based on the sequence specific for the CTX-M group (e.g., CTX-M
167.M1 and CTX-M 167.M9), were designed. In several cases an alternative
probe design was applied. (i) The probe set for positions 238 and 240 within the
SHV amino acid sequence, which covers the ESBL-relevant substitutions G238S,
G238A, and E240K (18), includes one perfect-match probe for each different
naturally occurring SHV sequence. As multiple combinations of amino acid
exchanges occur, a set of nine probes was designed and named according to the
amino acids at positions 238/240 (GE, SE, SK, AE, and AK) and the last
nucleotide within the codon for amino acid 240 (GEa or GEg). (ii) At or around
several amino acid positions, the mutant sequence differs in more than a single
nucleotide from the wild-type sequence (e.g., TEM position 35 [GA to CC]; SHV
position 140 [GGCC to CCGG], 192/193 [GC to CG], or 167 [insertion of 15
nucleotides—DRWET, or Asp-Arg-Trp-Glu-Thr]). Here, one probe each was
designed matching the wild-type (WT) and the mutant (MUT) sequence and
designated, for example, 140WT and 140MUT. For the wild-type sequence, the
sequences of the parental genes TEM-1, SHV-1, and CTX-M-1 (or CTX-M-2 or
CTX-M-9 for other CTX-M groups) were used. (iii) The sequences of several
probe sets (e.g., probe set SHV 61, TEM 224, etc.) contain artificial mismatches
to the target sequence at certain positions involved in hairpin or duplex forma-
tion to decrease the stability of such secondary structures, which hinder the
hybridization event. To compensate for the loss of hybridization efficiency asso-
ciated with such a method, the probe length usually had to be elongated to match
a Tm mismatch (also calculated with OligoAnalyzer) within the desired Tm range
(as described above). Where required, different versions of a probe set were
tested, and the one showing the best PM-MM discrimination and hybridization
efficiency using the applied hybridization conditions was selected. Sequences of
all probes included on the chip are shown in Table S1 in the supplemental
material.
Oligonucleotide array fabrication. Oligonucleotide arrays consisted of three
stripes of subarrays, each representing a chip module for the detection of TEM,
SHV, or CTX-M beta-lactamases. Every array was manufactured with 618 dif-
ferent oligonucleotide capture and control probes. The oligonucleotides were
purchased from Metabion (Planegg-Martinsried, Germany) in desalted purity
and quality controlled by matrix-assisted laser desorption ionization–time-of-
flight mass spectrometry. Each oligonucleotide was equipped with a 13-thymi-
dine spacer and an amino modification at the 5 end. Each beta-lactamase
gene-specific probe was spotted onto the microarray in triplicate. The array
production process and the subsequent washing steps were carried out as de-
scribed previously (26), with modifications. In brief, a BioRobotics MicroGrid II
microarrayer (Genomic Solutions Ltd., Huntingdon, United Kingdom) with
eight tungsten split pins (PT3000; Point Technologies, Boulder, CO) was used to
VOL. 48, 2010 GENOTYPING DETECTION OF ESBL RESISTANCE 461
 o
n
 June 16, 2013 by UNIVERSITY O
F EDINBURG
H
http://jcm.asm.org/
D
ow
nloaded from
 
print the oligonucleotide probes, which were dissolved in spotting buffer (Nex-
terion Spot with 0.0075% Triton X-100 [final concentration]; Schott, Jena, Ger-
many) to a final concentration of 20 M (except for the spotting control [5 M]
and 11 different capture probes of the CTX-M chip module [12 to 50 M]) onto
epoxy-coated glass slides (Nexterion Slide E; Schott, Jena, Germany). For cova-
lent immobilization, the oligonucleotide array was incubated at 60°C for 30 min
in a drying compartment (Memmert, Schwabach, Germany). After being spotted,
the slides were rinsed for 5 min in 0.1% (vol/vol) Triton X-100 in double-distilled
H2O (ddH2O), 4 min in 0.5 l of concentrated HCl per ml of ddH2O, and 10 min
in a 100 mM KCl solution with constant stirring. Subsequently, the slides were
incubated in blocking solution (25% [vol/vol] ethylene glycol in ddH2O, 0.5 l of
concentrated HCl per ml of blocking solution) with the spotted side upwards at
50°C in a heating compartment (OV5; Biometra, Go¨ttingen, Germany), rinsed in
ddH2O for 1 min, and finally dried under a flow of nitrogen. The average spot
size was 130 m, and the spot-to-spot distance was 320 m. The processed slides
were stored dry at room temperature in the dark for a maximum of 20 days until
further use.
Controls. In addition to the beta-lactamase gene-specific probes, each array
included several controls: a prelabeled spotting control (5-TTTTTTTTTTTTT
TCTAGACAGCCACTCATA-cyanine3 [Cy3]-3), a positive hybridization con-
trol (5-TTTTTTTTTTTTTGATTGGACGAGTCAGGAGC-3) complemen-
tary to a labeled oligonucleotide target (5-Cy3-GCTCCTGACTCGTCCAATC-
3), which was spiked during hybridization, and a negative hybridization control
(5-TTTTTTTTTTTTTTCTAGACAGCCACTCATA-3). All of these control
sequences are unrelated to sequences found in bacterial species. The spotting
controls were set at the corner positions of each of the 14 subarrays. The positive
and negative hybridization controls were spotted alternately at the side borders
of each subarray. The sequences of the process controls (TEM, 5-TTTTTTTT
TTTTTAGAAACGCTGGTGAAAGT-3; SHV, 5-TTTTTTTTTTTTTTTTA
AAGTAGTGCTCTGCGGC-3; CTX-M, 5-TTTTTTTTTTTTTTATCGCGG
TGATCTGGC-3) corresponded to sequences conserved within the blaTEM,
blaSHV, and blaCTX-M gene families. Within the subarrays belonging to a certain
chip module, the corresponding process control was spotted in two lines border-
ing the central probe sets (Fig. 1; also see Fig. S1 in the supplemental material).
Amplification, labeling, and purification of target DNA. The target DNA used
for hybridization on the oligonucleotide arrays was amplified by PCR. The
blaTEM and blaSHV genes were amplified simultaneously in a dual-plex PCR
using the primers TEM-forw (5-TGAGTATTCAACATTTCCGTGT-3),
TEM-rev (5-TTACCAATGCTTAATCAGTGA-3), SHV-forw (5-CAAAAC
GCCGGGTTATTC-3), and SHV-rev (5-TTAGCGTTGCCAGTGCT-3),
with expected amplicon lengths of 861 and 937 bp, respectively. For amplification
and labeling, 50 ng plasmid DNA was supplemented with 0.4 M (each) primers;
100 M (each) dATP, dGTP, and dTTP; 60 M dCTP; 40 M Cy3-dCTP (ratio
of unlabeled/labeled dCTP, 3:2) (GE Healthcare, Munich, Germany); 1 PCR
buffer containing 2.5 mM Mg(OAc)2 (Eppendorf, Hamburg, Germany); 2%
dimethyl sulfoxide (Fluka Chemie, Buchs, Switzerland); and 5 U of Taq DNA
polymerase (Eppendorf, Hamburg, Germany) in a total volume of 50 l. An
initial denaturation at 94°C for 1 min was followed by 30 cycles of 94°C for 30 s,
54°C for 30 s, and 68°C for 1 min, with a final extension step at 68°C for 4 min.
For the detection of blaCTX-M genes, a multiplex PCR was carried out using
primers described by Woodford et al. (52), which leads to different amplicon
sizes for the different blaCTX-M groups. For the amplification, 50 ng template
DNA was supplemented with primers (each at 0.2 M, except for 0.4 M for the
M9 group primer pair) and Qiagen multiplex PCR master mix (Qiagen, Hilden,
Germany) containing optimized concentrations of HotStarTaq DNA polymer-
ase, MgCl2, deoxynucleoside triphosphates, and reaction buffer in a total volume
of 50 l. An activation step at 95°C for 15 min was followed by 35 cycles of 94°C
for 30 s, 60°C for 90 s, and 72°C for 1 min, and a final extension step at 72°C for
10 min. Detected blaCTX-M genes were amplified and labeled to produce target
DNA using the corresponding CTX-M group-specific primer pair. The primers
were described previously by Eckert et al. (16). The expected amplicon lengths
were 864 bp for CTX-M1 and 870 bp for the CTX-M9 group. The labeling PCR
protocol described for the amplification of blaTEM and blaSHV genes was used
with the following modifications: primer concentration, 0.2 M; annealing tem-
perature, 60°C. To screen for blaCMY-2-like AmpC genes originating from
Citrobacter freundii, the primers CIT-forw (5-CGGACACCTTTTTGCTTTTA
ATT-3) and CIT-rev (5-GAAAAAAAGAGAAAGAAAGGAGGC-3) were
used by applying the TEM/SHV dual-plex PCR protocol. Amplifications were
performed in a Mastercycler gradient or gradient S (Eppendorf, Hamburg,
Germany). A no-template negative control was included in each PCR run. After
the purification of the PCR product with the QIAquick Spin PCR purification kit
(Qiagen, Hilden, Germany), the DNA concentration and the rate of the incor-
poration of Cy3-dCTP, expressed as the number of nucleotides/number of in-
corporated fluorescent dyes (NT/F), was determined by the measurement of the
optical density (ND-1000 spectrophotometer; NanoDrop Technologies, Rock-
land, ME).
DNA sequencing. For DNA sequencing, the blaTEM, blaSHV, and blaCTX-M
genes detected in clinical samples subsequently were amplified in separate re-
actions. Amplifications were carried out using the same primer pairs (TEM-forw
and TEM-rev, SHV-forw and SHV-rev, and CTX-M group-specific primer pairs)
and the same PCR conditions as those described for the production of target
DNA but without applying Cy3-labeled dCTP; 100 M dCTP was used instead.
A no-template negative control was included in each PCR run. The PCR product
was purified with the QIAquick spin PCR purification kit (Qiagen, Hilden,
Germany) according to the protocol of the manufacturer. The DNA was eluted
in 30 l of ddH2O. The purified PCR products were sequenced with the follow-
ing primers: blaTEM genes, TEM-forw, TEM-rev, TEMseq-forw (5-GCCAAC
TTACTTCTGACAAC-3), and TEMseq-rev (5-GCCAACTTACTTCTGACA
AC-3); blaSHV genes, SHV-forw, SHV-rev, SHVseq-forw (5-GGATTGACTG
CCTTTTTGC-3), and SHVseq-rev (5-GCAAAAAGGCAGTCAATCC-3);
blaCTX-M group M1 genes, CTX-M1-forw (5-GGTTAAAAAATCACTGCGT
C-3), CTX-M1-rev (5-TTGGTGACGATTTTAGCCGC-3), CTX-M1seq-forw
(5-GCGATGTGCAGCACCAGTAA-3), and CTX-M1seq-rev (5-AGCTTAT
TCATCGCCACGTT-3); blaCTX-M group M9 genes, CTX-M9-forw (5-ATGG
TGACAAAGAGAGTGCA-3), CTX-M9-rev (5-CCCTTCGGCGATGATTC
TCG-3), CTX-M9seq-forw (5-CCAATGTGCAGTACCAGTAA-3), and
CTX-M9seq-rev (5-ATTGGAAAGCGTTCATCACC-3). Sequencing was pro-
vided by GATC-Biotech (Konstanz, Germany). All bla genes detected were
sequenced in both directions with two primers each, resulting in four overlapping
fragments. The sequence data were assembled by using SeqMan II software
(version 5.00; DNAStar, Madison, WI).
Fragmentation. Target DNA for the hybridization on two chips (duplicate)
was fragmented with 0.4 mU DNase I (Promega, Mannheim, Germany) per ng
labeled target DNA to increase the efficiency of hybridization and avoid dena-
turation. All target DNAs amplified from one isolate were included in the same
reaction. The fragmentation was carried out in 1 reaction buffer (40 mM
Tris-HCl [pH 8], 10 mM MgSO4, 1 mM CaCl2) at room temperature for 5 min
in a total volume of 20 to 30 l depending on the concentrations of the purified
PCR products. The reaction was stopped by the addition of 2 mM EGTA and
incubation at 65°C for 10 min. Fragment sizes were estimated to be in the range
of 15 to 150 bp using lab-on-a-chip electrophoresis (Bioanalyzer 2100, DNA 1000
LabChip kit; Agilent, Bo¨blingen, Germany).
Hybridization. Depending on the presence of either one or both genes, 150 or
200 ng TEM/SHV target DNA was hybridized. For CTX-M, 150 ng target DNA
was used. As standard conditions, the fragmented target DNA for one slide
together with DNA complementary to the positive control (Cy3-GCTCCTGAC
TCGTCCAATC; 0.05 pmol) was hybridized in 65 l of 2 SSPE (1 SSPE is
0.18 M NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.7]) containing 0.1%
sodium dodecyl sulfate (SDS). For hybridization, an HS400 automated hybrid-
ization station (Tecan, Crailsheim, Germany) was used with an initial wash step
at 47°C for 30 s with 2 SSPE (the same concentration as that used for the
hybridization solution) followed by the injection of 65 l hybridization solution
and hybridization at 47°C for 1 h using a high agitation frequency. After hybrid-
ization, the slides were washed two times at room temperature: 1.5 min with 2
SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate), 0.1% SDS, and 1.5
min with 0.2 SSC. The slides subsequently were dried with N2 at 30°C for 4 min.
The duration of the whole procedure was 90 min. Different SSPE and SDS
concentrations or hybridization temperatures were tested during assay optimi-
zation.
Data acquisition and processing. After the hybridization reaction, the data
from the oligonucleotide arrays were read out by the acquisition of the fluores-
cence signals using a ScanArray Express microarray scanner (Perkin-Elmer,
Waltham, MA). The laser power setting was 100%. Each slide was scanned with
multiple photomultiplier tube (PMT) gain settings, including 55, 60, 65, and 70%
and a 10-m resolution. The image processing and calculation of signal inten-
sities were performed with ScanArray Express analysis software, version 3.0
(Perkin-Elmer, Waltham, MA). Individual net signal intensities were calculated
by the subtraction of the local background from the raw spot intensity value.
Further data processing was performed using Microsoft Excel (Microsoft, Red-
mond, WA). Unless otherwise noted, the standard data processing procedure as
follows. Net signal intensities were extracted from the PMT 60% scans. For the
calculation of the mean net signal intensities, referred to as signal intensity, the
six spot replicates of a certain oligonucleotide probe on two identically processed
microarrays (three replicates each) were used. Standard deviations also were
calculated.
Within each oligonucleotide probe set related to a certain mutation, the probe
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showing the highest signal intensity was considered the potential perfect match
(PM). The remaining ones with lower signal intensities were considered mis-
matches (MM). The quality of the discrimination between single nucleotides
within the target using such a probe set is reflected by the difference between the
perfect match signal and mismatch signals. Therefore, the ratio between the
individual net signal intensity of each spot replicate of a certain probe within
the probe set (NISpot) and the mean signal intensity of the perfect match signal
(IPM) was calculated (NIspot/IPM). The mean of those values is referred to as the
relative intensity (RI or RIMEAN) of a certain oligonucleotide probe. Accord-
ingly, the perfect matches always had RI values of 1 (RIPM  1), and the relative
FIG. 1. Chip layout. (a) Fluorescence image after hybridization with 200 ng labeled TEM-1/SHV-1 (NT/F  71) and 150 ng CTX-M-15
(NT/F  97) target DNA (Iso-37; PMT, 60%). Box 1, fluorescence signals of some process controls; box 2, probe sets for CTX-M group
determination; box 3, signal pattern of probe set TEM 39. The signal intensity is encoded in the 65,636 gray scales of the 16-bit TIF image.
(b) Schematic representation of the modular layout of the oligonucleotide microarray. The areas specific for the different beta-lactamase
genes and the different subgroups of the CTX-M type genes are labeled. The enlarged part describes in detail the arrangement of the A,
G, C, and T probes of each probe set. The probe sets are named as described in Materials and Methods, and numbers represent interrogated
amino acid positions. Theoretical perfect matches after hybridization with TEM-1, SHV-1, CTX-M-1, CTX-M-2, CTX-M-8, and CTX-M-9
are highlighted in black. An enlarged version of this figure is shown in Fig. S1 in the supplemental material.
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intensities of the mismatches have values below 1 (RIMM 	 1). Standard devi-
ations also were calculated.
For the evaluation of the performance of each probe set, the median of the
relative intensities (NIspot/IPM) of the six technical replicates (three spots on two
arrays each) were calculated and referred to as RIMEDIAN. The means and
standard deviations from the RIMEDIAN values of repeated experiments (bio-
logical replicates) were calculated, and the means again were referred to as
relative intensity (RI). The probe sets of the TEM module were analyzed using
data of all clinical isolates harboring a TEM-1 gene (n  38). For the SHV
module, all SHV-1-positive isolates (n  10) were used, and for the CTX-M
module, all CTX-M-15 (n 34)- or CTX-M-14/M-9 (n 3 to 8)-positive isolates
were used. Signals obtained from mixed genotypes were evaluated calculating the
95% confidence intervals in addition to standard deviations. Standard t testing
was applied where necessary.
Nucleotide sequence accession numbers. The sequences obtained by sequenc-
ing have been submitted to GenBank under accession numbers FJ668714 to
FJ668818.
RESULTS
In the present study, we describe a diagnostic oligonucleo-
tide microarray for the rapid identification of ESBLs in Entero-
bacteriaceae by the simultaneous genotyping of TEM, SHV,
and CTX-M beta-lactamase genes. The performance of this
integrated chip and its applicability as an identification tool
was validated using 60 blinded clinical samples collected in two
clinical laboratories. The current version of the chip includes
probe sets for the identification of 99% of all TEM variants
and 89% of all SHV variants published (http://www.lahey.org
/studies/; as of 2008). All positions known to be associated with
ESBL activity (18) and inhibitor resistance (8) were included.
Probes within the CTX-M chip module cover CTX-M group
determination and the identification of 82% of all known
CTX-M group M1 beta-lactamases as well as 83, 50, and 50%
of all group M2, group M9, and group M8/M25 beta-lacta-
mases.
ESBL chip development. The development of the described
chip included the integration of previously designed chips for
different beta-lactamase genes as well as the integration of
newly designed and redesigned probe sets. An easily expand-
able modular organization was chosen as the layout (Fig. 1;
also see Fig. S1 in the supplemental material). During the
integration process, reference strains with known gene variants
were used and several adjustments to hybridization parameters
were made compared to those of our previous studies (19). As
standard conditions, the hybridization of fragmented target
DNA was carried out for 1 h at 47°C in a solution containing
2 SSPE and 0.1% SDS. The application of the automated
hybridization station resulted in a hybridization procedure of
only 90 min, including washing and drying steps. The data
acquisition was possible immediately afterwards.
For the production of target DNA, plasmid DNA isolated
from clinical samples or from reference material was amplified
by PCR. For the simultaneous genotyping of different gene
targets, a multiplexed amplification and labeling strategy is
desirable. TEM and SHV genes were amplified and labeled
with Cy3 using a robust dual-plex PCR. Amplification product
sizes were 867 and 927 bp, respectively. The integration of the
CTX-M amplification into a multiplexed format, which would
simultaneously amplify and label all of the TEM, SHV, and
CTX-M genes, was dropped due to the formation of het-
erodimers between primers specific for the different CTX-M
groups. Hence, CTX-M target DNA was amplified with group-
specific primers in a singleplex PCR after clarifying the allo-
cation to a certain CTX-M group by using a multiplex screen-
ing PCR. The PCR product sizes for CTX-M1 and CTX-M9
group members were 864 and 870 bp, respectively. The Cy3
incorporation rates were similar for all labeling PCRs applied.
The mean NT/F ratios (variation depending on template qual-
ity) of the TEM/SHV PCR products were 84 (45 to 170) and 97
(56 to 173), respectively, for the CTX-M group-specific PCR
products.
The performance of an individual probe set was assessed
with regard to its discrimination power for various DNA tar-
gets and expressed as the mismatch-to-perfect match ratio
(MM/PM). For allele-specific hybridization, which was chosen
as a format in the presented microarray, the probe position
relative to that of the target is virtually fixed if single-nucle-
otide polymorphisms are targeted. However, at certain posi-
tions it was impossible to select probes, because stable second-
ary structures would have formed within the probe themselves,
rendering a meaningful detection impossible. We therefore
chose to incorporate artificial mismatches at positions involved
in the undesired secondary structure formation at difficult tar-
get positions. Figure 2 compares the standard and alternative
probe designs for probe sets SHV 61 and TEM 224. In both
cases, the probe containing a cytosine represents the perfect
match when hybridizing SHV-1 and TEM-116 target DNA.
For SHV 61, the replacement of a cytosine by thymine at a
position significantly involved in dimer formation shifted the
highest hybridization signal from the wrong A probe to the
correct C probe. The highest mismatch signal of the resulting
probe set showed only 52% of the perfect match signal. In
another case, the performance of the already correct working
probe set TEM 224 was further improved by the same method
(Fig. 2). Here, the average RIMM value was decreased from
0.32 to 0.11. For a complete list of all probes used for the
current version of the chip, see Table S1 in the supplemental
material.
Testing of clinical isolates. The performance of the array
was validated using 60 blinded samples containing DNA iso-
lated from clinical isolates collected in clinical routines of the
Department of Clinical Chemistry and Laboratory Medicine at
the Robert Bosch Hospital (RBK) in Stuttgart and the Insti-
tute of Medical Microbiology and Infection Control of the
J. W. Goethe-Universita¨t in Frankfurt am Main. Fifty-eight
were phenotypically characterized as ESBL positive using stan-
dard laboratory procedures for susceptibility testing (agar dif-
fusion using CLSI breakpoints; Vitek 2). Two samples showed
an ambiguous or ESBL-negative phenotype (Iso-23 and Iso-
62). The identified species were mainly E. coli and different
Klebsiella species, but also one isolate each of Enterobacter
sakazakii, E. intermedius, Proteus vulgaris, C. freundii, and Rah-
nella aquatilis (Table 1).
Prior to the genotyping with the integrated ESBL chip, all
samples were screened by the described amplification proce-
dures for the presence of the target genes. As a result, 63% of
all 60 isolates were positive for blaTEM, 38% for blaSHV, and
70% for blaCTX-M; 3% were negative for all targets. From all
isolates found to be E. coli, 55% harbored blaTEM, 3% blaSHV,
and 94% blaCTX-M. For Klebsiella spp., 69% were positive for
blaTEM, 81% for blaSHV, and 58% for blaCTX-M. With the
applied multiplex screening PCR for blaCTX-M it was possible
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to distinguish between different CTX-M groups. The highest
prevalence within the CTX-M-positive isolates was found for
group M1 (81%), followed by 14% for group M9 and 4% for
group M1 and M9 together.
The further identification of the isolates’ beta-lactamase ge-
notype was based on a hierarchical readout of the DNA mi-
croarray signals after labeling PCR and hybridization to the
ESBL chip. As an example, Fig. 1a shows the hybridization
result for Iso-37. (i) The gene family was determined by the
process controls (PC), which act as gene family-specific probes.
For Iso-37, the PCs detected the presence of a TEM, SHV, and
CTX-M gene (box 1). (ii) The classification of detected
CTX-M genes into subgroups (M1, M2, M9, and M8/25) was
done by four probe sets (see the layout section labeled CTX-M
group in Fig. 1b). The Iso-37 CTX-M gene showed the char-
acteristic hybridization signal pattern for a blaCTX-M-1-like
gene as indicated by the identified adenosine (A) for probe set
73.M1/2, the absent signal for probe set 73.M9, and the iden-
tified guanosines (G) for probe sets 132 and 267 (box 2). (iii)
Finally, the beta-lactamase gene variant was identified by sig-
nal patterns exhibited by the individual probe sets correspond-
ing to the different interrogated mutation positions. For exam-
ple, when hybridizing the Iso-37 TEM gene, the signal pattern
of probe set 39 (box 3) identified the presence of cytosine (C)
and therefore a TEM-1 (wild-type) codon at this position
(box3). None of the other TEM probe sets identified a point
mutation. Hence, the gene was identified as blaTEM-1. The
SHV gene also was identified as the parental blaSHV-1 gene, as
no mutation was identified. The CTX-M gene was identified as
blaCTX-M-15 due to the specific mutations identified with the
probe sets 77, 114, 140, 240, and 288 (compare theoretical
perfect matches after hybridization with blaCTX-M-1 and the
actual hybridization signals for Iso-37). The results for all 60
isolates are summarized in Table 1. In 54 isolates an ESBL
gene variant was detected, whereas 6 isolates contained no
TEM-, SHV-, or CTX-M-derived ESBL. All blaTEM genes
coded for TEM-1, meaning that no ESBL phenotype could be
assigned to TEM. For SHV, a range of gene variants was
detected covering SHV-1, SHV-12, and SHV-5. CTX-M-15
and CTX-M-3 were found as members of CTX-M group M1
and CTX-M-9, CTX-M-14, and CTX-M-14b as members of
the group M9. SHV- and CTX-M ESBLs were detected in the
following combinations: CTX-M (72.2%, 39/54), SHV (22.2%,
12/54), 2 CTX-M (3.7%, 2/54), and SHV plus CTX-M (1.9%,
1/54). SHV-12 was the most prevalent SHV-ESBL (84.6%,
11/13), CTX-M-15 the most frequently detected CTX-M-
ESBL (81%, 34/42). SHV-ESBLs were found mainly in Kleb-
siella species (84%), CTX-M group M9 ESBLs in E. coli
(87%), and CTX-M group M1 ESBLs in E. coli and Klebsiella
at similar frequencies (55 and 41%). All DNA array results
were confirmed by Sanger sequencing. The three E. coli iso-
lates Iso-34, Iso-44, and Iso-53 did not harbor a TEM-, SHV-,
or CTX-M ESBL gene and also were found to be negative in
a separate PCR screening for the presence of a blaCMY-2-like
AmpC gene.
Table 1 also includes the ceftazidime (CAZ) and cefotaxime
(CTX) MICs for the different clinical samples obtained by
measurements with the Vitek 2 Gram-negative susceptibility
card (AST-N062). SHV-5 and SHV-12 both feature the
Glu240Lys mutation in combination with Gly238Ser, which is
FIG. 2. Alternative probe design. Shown is the effect of the incorporation of an artificial mismatch at a position involved in dimer formation
on the identification capability of probe set SHV 61. The improvement of the performance of probe set TEM 224 also is shown. Standard and
alternative probe sets were printed within the same array and hybridized simultaneously. Data are based on hybridization experiments under
standard conditions with TEM-3 (NT/F  72) and SHV-1 (NT/F  30) target DNA.
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TABLE 1. Genotyping of clinical isolates
No.a Isolateb
Array resultc MIC (g/ml)
blaTEM blaSHV blaCTX-M CTX CAZ CTX/CAZ ESBL testd
24* E. sakazakii TEM-1 SHV-12 4 32 	1
55* K. oxytoca TEM-1 SHV-12 4 8 	1 Pos
25* Klebsiella sp. SHV-12 16 64 	1
2
 K. pneumoniae TEM-1 SHV-12 (
SHV-1) 16 64 	1 Pos
12
 K. pneumoniae TEM-1 SHV-12 (
SHV-1) 64 64 Pos
36
 K. pneumoniae TEM-1 SHV-12 (
SHV-1) 4 64 	1 Pos
1
 K. terrigena TEM-1 SHV-12 (
SHV-1) 32 64 	1
15
 K. terrigena TEM-1 SHV-12 (
SHV-1) 32 64 	1
17
 K. terrigena TEM-1 SHV-12 (
SHV-1) 64 64
52* Klebsiella sp. TEM-1 SHV-12 (
SHV-1) 32 64 	1 Pos
5
 E. coli SHV-5 1 64 	1 Pos
19
 K. pneumoniae SHV-5 64 64 Pos
49* Klebsiella sp. TEM-1 SHV-12 CTX-M-15 64 64
13
 E. coli TEM-1 CTX-M-15 64 16 1 Pos
18
 E. coli TEM-1 CTX-M-15 64 64 Pos
20* E. coli TEM-1 CTX-M-15 64 32 1 Pos
26
 E. coli TEM-1 CTX-M-15 64 16 1 Pos
33* E. coli TEM-1 CTX-M-15 64 32 1 Neg
38
 E. coli TEM-1 CTX-M-15 64 64 Pos
40
 E. coli TEM-1 CTX-M-15 64 16 1 Pos
48* E. coli TEM-1 CTX-M-15 64 16 1 Pos
60
 E. coli TEM-1 CTX-M-15 64 16 1 Pos
61
 E. coli TEM-1 CTX-M-15 64 64 Pos
6
 E. coli CTX-M-15 64 16 1 Pos
9
 E. coli CTX-M-15 64 64 Pos
30* E. coli CTX-M-15 64 16 1 Pos
32* E. coli CTX-M-15 64 16 1 Pos
34
 E. coli CTX-M-15 64 16 1 Pos
57
 E. coli CTX-M-15 64 16 1 Pos
3
 E. intermedius CTX-M-15 64 64
29
 K. oxytoca SHV-1 CTX-M-15 64 64 Pos
7
 K. pneumoniae TEM-1 SHV-1 CTX-M-15 64 16 1 Pos
16
 K. pneumoniae TEM-1 SHV-1 CTX-M-15 64 64 Pos
37
 K. pneumoniae TEM-1 SHV-1 CTX-M-15 64 64 Pos
10
 K. pneumoniae SHV-1 CTX-M-15 Pos
35
 K. pneumoniae SHV-1 CTX-M-15 64 64 Pos
42
 K. pneumoniae SHV-1 CTX-M-15 64 64 Pos
11
 K. pneumoniae TEM-1 CTX-M-15 64 16 1 Pos
22* K. pneumoniae TEM-1 CTX-M-15 64 64 Pos
50* K. pneumoniae TEM-1 CTX-M-15 64 64 Pos
14
 K. terrigena TEM-1 SHV-1 CTX-M-15 64 64
28
 K. terrigena SHV-1 CTX-M-15 64 64
21* K. terrigena TEM-1 CTX-M-15 64 64
51* Klebsiella sp. TEM-1 CTX-M-15 64 64
8
 E. coli TEM-1 CTX-M-3 32 4 1 Pos
56* E. coli CTX-M-3 16 1 1 Pos
59
 E. coli TEM-1 CTX-M-15 
 CTX-M-14b 64 64 Pos
27
 E. coli TEM-1 CTX-M-15 
 CTX-M-14b 64 64 Pos
4
 E. coli TEM-1 CTX-M-14 64 1 1 Pos
39
 E. coli TEM-1 CTX-M-14 64 1 1 Pos
58
 E. coli CTX-M-14 64 1 1 Pos
46* E. coli TEM-1 CTX-M-9 4 64 	1 Pos
41
 E. coli CTX-M-9 64 4 1 Pos
47
 P. vulgaris CTX-M-9
44* E. coli TEM-1 32 64 	1 Pos
53* E. coli TEM-1 64 16 1 Pos
31* E. coli TEM-1 32 64 	1 Pos
54* Citrobacter freundii 32 64 	1
62* Klebsiella pnemoniae SHV-1
23* Rahnella aquatilis 1 1
a Data were sorted first by the different genotypes detected and afterwards were clustered by species. Isolate numbers were used for labeling the blinded plasmid
isolates: *, samples originally collected in Stuttgart; 
, samples originally collected in Frankfurt. Samples Iso-27 and Iso-59 originated from the same patient but different
specimens (Iso-27, urine; Iso-59, respiratory sample).
b Species were identified as described in Materials and Methods.
c Array results were validated by standard the DNA sequencing of the PCR product received.
d The Vitek ESBL test is FDA approved only for E. coli, K. pneumoniae, and K. oxytoca. Pos, positive; Neg, negative.
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known to shift the substrate specificity toward ceftazidime (18).
Generally, a CTX/CAZ MIC ratio of 	1 was observed for the
samples harboring those ESBLs. Typically, CTX-M enzymes
favor cefotaxime over ceftazidime as a substrate. This leads to
the observed CTX/CAZ ratio of 1 for the CTX-M ESBLs.
CTX-M-15 features the Asp240Gly mutation, which is thought
to increase activity against ceftazidime compared to that of
CTX-M-3, -M-9, or -M-14 (4, 5). This trend also was observed.
Only sample Iso-46 showed a deviant behavior with a CTX-
M-9 gene present and a CTX/CAZ ratio of 	1. For the full
Vitek data set as well as standard susceptibility testing results,
see Table S2 in the supplemental material.
Chip performance. The performance of the ESBL chip was
assessed according to the distribution of RIMM values across
defined RIMM ranges, as displayed in Fig. 3. For the perfor-
mance analysis, all experiments leading to the same perfect
match signals were subsumed as replications. For the whole
ESBL chip, 94% of all MM signals had an RIMM of 	0.4,
which demonstrated the excellent discrimination capacity of
the setup. The three chip modules showed similar distributions
of mismatch signals, with the SHV chip being the most specific
(Fig. 3b). The performances of individual probe sets relevant
for the genotyping of blaTEM, blaSHV, and group M1 and M9
blaCTX-M genes are displayed in Fig. 4. The vast majority of the
135 probe sets identified the present nucleotide without ambi-
guity. Intermediate RIMM values (0.5 to 0.7) were found for
TEM 42, TEM 280, TEM 237.2, SHV 43, CTX-M-231, CTX-
M-23, and CTX-M-77. These probe sets are potential candi-
dates for improvement by redesign. The only probe set that did
not work correctly in all relevant hybridizations was CTX-M-
29. However, this behavior could be assigned to an artifact of
the array printing process and not probe properties.
One remarkable property of the ESBL chip is its ability to
detect mixed genotypes (alleles) of the same beta-lactamase
family. Our study samples Iso-1, Iso-2, Iso-12, Iso-15, Iso-17,
Iso-36, and Iso-52 were reliably positive by the chip for
SHV-12 in the presence of SHV-1. The signals obtained at the
relevant positions 35 and 238/240 for isolates containing either
SHV-1, SHV-12, or a mixture of both are displayed in Fig. 5a.
The chip clearly could discriminate between the different sit-
uations, as the signals of the T probe at position 35 and the
GEg probe of probe set 238/240 were significantly different
(nonoverlapping confidence intervals; P 	 0.05 by t test). For
confirmation, Fig. 5b includes the Sanger sequencing results
for the Iso-24, Iso-37, and Iso-2 SHV-PCR products. At the
mutation sites, clear double peaks were apparent. For samples
Iso-59 and Iso-27, two CTX-M ESBLs were detected simulta-
neously, namely, CTX-M-15 and CTX-M-14b. The group dis-
crimination probe set 267 is relevant for such a mixture. The
signal at the T probe of this probe set was significantly different
when a CTX-M group M9 gene (CTX-M-14b) was hybridized
in addition to a group M1 gene (CTX-M-15) compared to a
group M1 gene alone (Fig. 5c).
DISCUSSION
With an increased prevalence of ESBL-producing patho-
gens, the fast and accurate identification of such isolates be-
comes increasingly clinically important. Despite a variety of
available methods, the identification of ESBLs by conventional
phenotypic methods remains difficult in practice due to the
large number of beta-lactamase variants, the association of
ESBLs with overproduced or plasmid-borne cephalosporinases
(AmpC) or metallo-beta-lactamases (MBL) (15), and the
change of outer-membrane permeability (28). Hence, molec-
ular methods that have the potential to disentangle this com-
plex resistance etiology and translate it into clinically useful
information have the potential to improve the current diag-
nostic practice. Multiplexing is a key requisite to cover this
task, and microarray platforms have been used repeatedly for
such purposes. Several studies described DNA microarrays for
the detection of various resistance gene panels, including some
beta-lactam resistance genes (11, 12, 25). These publications
used PCR products (200 to 800 bp) or long oligonucleotide
(70mer) probes (6, 17), which are not suitable for gene variant
discrimination at the single-nucleotide level. A more refined
FIG. 3. Performance of the whole chip (a) and individual chip modules (b). The distribution of RIMM values across different RIMM ranges is
displayed. The total amount of mismatch probes is 394 for the whole chip and 154, 135, and 105 for the TEM, SHV, and CTX-M chip modules,
respectively. Relative intensities of the probe sets are averaged from data of all clinical isolates harboring the TEM-1 (n  38), SHV-1 (n  10),
CTX-M-15 (n  34), and CTX-M-14/M-9 (n  3 to 8) genes.
VOL. 48, 2010 GENOTYPING DETECTION OF ESBL RESISTANCE 467
 o
n
 June 16, 2013 by UNIVERSITY O
F EDINBURG
H
http://jcm.asm.org/
D
ow
nloaded from
 
chip was described by Batchelor and colleagues, who devel-
oped an oligonucleotide microarray that covered beta-lactam
resistance genes with 14 probes (3). Most of their targets,
including blaTEM and blaSHV, were detected on a family level
using group-specific probes. The blaCTX-M genes were detected
on a subgroup level with three probes specific for CTX-M-1-
like, CTX-M-2-like, and CTX-M-9-like genes. Another similar
study recently reported a microarray-based method to detect
FIG. 4. Performance of 135 individual probe sets on the basis of the analysis of clinical isolates. Relative intensities and standard deviations of
the TEM, SHV, and CTX-M probe sets were calculated from data of all clinical isolates harboring the TEM-1 (n  38), SHV-1 (n  10),
CTX-M-15 (n 34), and CTX-M-14/M-9 (n 3 to 8) gene. Values of the four probes (A, G, C, and T) of each probe set are displayed in different
shades of gray as indicated in the legend. The CTX-M chip module figure is divided into CTX-M group M1 and M9 performance. Probe sets for
group and variant identification are separated.
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blaTEM, blaSHV, and blaCTX-M in combination with plasmid-
encoded AmpC beta-lactamase genes (54). The level of detec-
tion was also on the gene family level, plus six point mutations
in the blaSHV gene. These studies all demonstrate strategies to
set up diagnostic systems that quickly give a deeper insight into
the genetic background of the beta-lactam resistance of a clin-
ical isolate. In this study, we aimed to further extend these
activities and cover all known gene variants of the three se-
lected beta-lactamase families. As a result, the DNA microar-
ray was able to genotype mutations within blaTEM, blaSHV, and
blaCTX-M genes, which account for their classification into dif-
ferent variants and define their resistance spectra. As an ex-
ample, the array was able to detect SHV-12 and SHV-5 in
different Klebsiella and E. coli isolates. In a study that retro-
spectively correlated ESBL types, including SHV-12 and
SHV-5, with treatment outcomes in bloodstream infections, it
was found that the therapy failed when ESBL-producing
strains were treated empirically with ceftazidime (51). If the
respective clinician had had the right information before
choosing this extended-spectrum cephalosporin, i.e., from a
hospital infection control, knowing that this type of organism
was present in the hospital, the type of empirical therapy could
FIG. 5. Detection of mixed SHV and CTX-M genotypes. (a) Relative signals for probe sets SHV 35 and SHV 238/240. The displayed intensities
were calculated by analyzing data for all isolates harboring SHV-1 (n  7), SHV-12 (n  4), or both (n  7). Error bars represent the 95%
confidence interval (CI) scores calculated. (b) Sequencing results at the relevant nucleotide positions for isolates containing blaSHV-1 (Iso-37),
blaSHV-12 (Iso-24), or a mixture of both (Iso-2). Depending on the different sequences, the potential perfect match probes are indicated (PM). (c)
Relative signals for group discrimination probe set CTX-M 267. The displayed intensities were calculated by analyzing data for all isolates
harboring a CTX-M group M1 gene (n  35), a CTX-M group M9 gene (n  6), or both (n  2). Error bars also represent the 95% confidence
interval scores calculated.
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have been based on the molecular surveillance data obtained
by the hospital, leading to alternative drug choices (e.g., imi-
penem [36]). With its short assay time, the ESBL array de-
scribed in this study has the potential to provide such infor-
mation faster than conventional susceptibility tests. At the time
of design, the ESBL chip could identify all known mutations in
the target genes. Naturally, such a DNA microarray would
have to be updated as new mutations emerge and are de-
scribed, but as we have experienced since our first study (19),
this can be done with a reasonable amount of time and effort.
With regard to the published literature, this progression cur-
rently is faster with the CTX-M type-beta-lactamases than the
TEM- and SHV-type beta-lactamases. CTX-M-type enzymes
are now the most prevalent beta-lactamase species worldwide
(40).
The performance of the new integrated chip was tested with
60 blinded clinical samples, which were phenotypically pre-
characterized mainly as ESBL positive (58 isolates). Using the
phenotypic characterization as the gold standard, our assay
showed 93% sensitivity (54 of 58) for the detection of ESBLs.
DNA microarray results and DNA sequencing were 100%
concordant. For four isolates, the resistance phenotype could
not be explained by the presence of a TEM, SHV, or CTX-M
ESBL gene. When calculating the sensitivity, it has to be con-
sidered that the phenotypic gold standard is contentious and
also error prone for ESBL detection. For example, the MICs
for CTX-M-15-positive E. coli isolate 33 were identical to those
for other CTX-M-15-positive E. coli isolates (see Table S2 in
the supplemental material), but a synergy-based Vitek ESBL
test was negative. Additionally, CLSI recommendations and
the Vitek ESBL test are valid only for E. coli, K. pneumoniae,
K. oxytoca, and Proteus mirabilis, but not for other Gram-
negative species like C. freundii or R. aquatilis. As a conse-
quence, the sensitivity could be underestimated. Molecular
methods like the described DNA microarray assay can be used
for a wide range of species, including AmpC producers like C.
freundii. As possible explanations for the phenotypic data from
the three E. coli isolates 31, 44, and 53, we anticipate the
presence of a plasmid-carried ampC gene (other than C. freun-
dii-derived blaCMY genes, as they could be experimentally ex-
cluded), promoter mutations within the chromosomal ampC
gene, metallo-beta-lactamases, alterations of the membrane
composition, or rare beta-lactamases. The fourth false-nega-
tive sample contained a C. freundii strain that could harbor a
derepressed chromosomal ampC gene. For all positive isolates,
the substrate spectra connected to the identified gene variants
and the phenotypically measured MIC data correlated very
well. The increased hydrolytic activity against ceftazidime of
the CTX-M-15 variant was especially apparent compared to
that of most other CTX-M variants, such as CTX-M-3, which
differs in only one point mutation from CTX-M-15. Since only
a small number of ESBL-negative isolates were included, the
DNA array achieved a theoretic specificity of 100%. However,
this value needs to be seen in context and the performance to
be confirmed in future studies including a larger number of
negative isolates.
A comparison of the prevalence and spread of ESBL-pro-
ducing Enterobacteriaceae in Europe (8) with the ESBL genes
identified in this study revealed a high concordance with the
current resistance situation. CTX-M enzymes have become
more and more predominant, and the blaCTX-M genes also
were by far the most prevalent ESBL genes found among the
tested isolates. CTX-M-15 has risen to prominence all over
Europe (27) and also was the most frequent CTX-M ESBL in
our study. CTX-M-15 was detected in E. coli as well as in
Klebsiella isolates. Within the SHV family, SHV-12 is one of
the most prevalent enzymes and has been reported all over the
world for K. pneumoniae (9). In our study, SHV-12 also was the
most prevalent SHV ESBL and was detected exclusively in
Klebsiella isolates. Interestingly, no TEM ESBL was identified.
More than 60% of the tested isolates harbored a blaTEM gene,
but all were identified as TEM-1 and thus not an ESBL. These
findings for TEM and SHV indicate that the detection of a
resistance gene family alone is not sufficient as a diagnostic
parameter.
Conclusions. We described an integrated oligonucleotide
microarray for the genotyping of TEM, SHV, and CTX-M
beta-lactamase variants at the single-nucleotide level within 5 h
and with a sensitivity of 93%. As it is, the DNA microarray
provides an interesting tool for epidemiological studies or sur-
veillance with unparalleled coverage. The integration of other
resistance genes is under way and will further increase its
information value. In addition, this study provides a key build-
ing block for the development of advanced antibiotic resistance
diagnostics, such as microfluidic sample-to-answer systems,
which integrate the microarray analysis with preanalytics and
readout. Their introduction into the clinical routine could con-
tribute to the prudent use of antibiotics and optimal treatment
outcome.
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